Related Experiment Video

Updated: Dec 14, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.2K

Neonatal hypoglycemia algorithms improve hospital outcomes

Erin A Plummer1, Ivana Ninkovic2, Anna Rees2

  • 1Department of Pediatrics, Division of Neonatology, University of Minnesota, Minneapolis, MN, USA.

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
|July 21, 2020
PubMed

Insights

Implementing hypoglycemia algorithms (HGA) streamlined care for at-risk newborns, reducing intravenous dextrose use and NICU admissions. The updated HGA, including dextrose gel, maintained benefits and cut costs, improving infant outcomes.

Area of Science:

  • Neonatal Medicine
  • Pediatrics
  • Healthcare Management

Background:

  • Neonatal hypoglycemia management protocols vary, impacting infant care and hospital resources.
  • Standardized hypoglycemia algorithms (HGA) can streamline treatment for at-risk newborns.

Purpose of the Study:

  • To implement and evaluate the impact of hypoglycemia algorithms (HGA) on neonatal hypoglycemia management.
  • To improve outcomes for the mother-infant dyad and reduce hospital costs associated with neonatal hypoglycemia.

Main Methods:

  • Retrospective cohort study of 4,666 asymptomatic infants at risk for hypoglycemia (2010-2016).
  • Analysis of outcomes across three epochs: pre-HGA (2010-2011), HGA1 (2012-2013), and HGA2 (2014-2016, including dextrose gel).
  • Cost savings calculated using linear regression.

Main Results:

  • HGA implementation reduced intravenous dextrose use compared to the pre-HGA period (3.9% to 2.5% and 1.0%).
  • The HGA2 group showed increased breastfeeding rates (86.7% to 88.4%) and decreased NICU admissions (10.6% to 9.4%).
  • Total cost savings approximated $222 per case, with no change in length of stay.

Conclusions:

  • Hypoglycemia algorithms (HGA) effectively improved short-term outcomes for asymptomatic infants at risk.
  • Updating HGA to include dextrose gel maintained benefits and further enhanced outcomes, reducing overall care costs.
  • Standardized HGA positively impacts neonatal care, promoting mother-infant bonding and cost-efficiency.
Abstract

Keywords:
Neonatal hypoglycemiaalgorithmoral dextroseoutcomes

More Related Videos

Biochemical Measurement of Neonatal Hypoxia13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

14.3K
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

411

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
679
SBAR II: Application of SBAR01:14

SBAR II: Application of SBAR

SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
5.5K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.9K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.5K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
480